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Abstract 
Stimuli-responsive and imaging-guided drug delivery systems hold vast promise for enhancement 
of therapeutic efficacy. Here we report an adenosine-5’-triphosphate (ATP)-responsive and 
near-infrared (NIR)-emissive conjugated polymer-based nanocarrier for the controlled release of 
anticancer drugs and real-time imaging. We demonstrate that the conjugated polymeric 
nanocarriers functionalized with phenylboronic acid tags on surface as binding sites for ATP could 
be converted to the water-soluble conjugated polyelectrolytes in an ATP-rich environment, 
which promotes the disassembly of the drug carrier and subsequent release of the 
cargo. In vivo studies validate that this formulation exhibits promising capability for inhibition of 
tumor growth. We also evaluate the metabolism process by monitoring the fluorescence signal of 
the conjugated polymer through the in vivo NIR imaging. 
Key words: drug delivery, nanomedicine, stimuli-responsive, ATP-responsive, theranostics, conjugated 
polymers. 
Introduction 
Nanocarrier-based drug delivery systems 
(DDSs) offer new opportunities to enhance 
therapeutic efficacy due to their improved bioactivity 
and enhanced bioavailability of drugs.[1-5] To further 
improve pinpoint therapeutic efficacy, various efforts 
have been devoted to explore stimuli-responsive[6, 7] 
and imaging-guided DDSs[8-11], which are 
specifically stimulated to release drugs within target 
sites and achieve real-time imaging-guided 
therapeutics. A broad range of stimuli have been 
explored to design smart DDSs, including the external 
triggers, such as light[12, 13], ultrasound[14], 
magnetism[15, 16], temperature[17], and electric 
field[18], as well as internal stimuli, such as pH[19, 
20], redox potential[21], oxidative stress[22, 23], 
enzyme[24, 25], and glucose levels[26, 27]. 
Imaging-guided DDSs have been rapidly developed 
by inorganic nanosystems with contrast properties 
made of carbon dots[28], quantum dots[29], 
metals[30], and metal oxide frameworks[31]. In 
addition, conjugated polymer nanoparticles, as 
special organic nanosytems, have remarkable 
photophysical properties which are also suitable for 
biological fluorescence imaging.[32-37] 
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Herein, we report an innovative conjugated 
polymer-based nanocarrier capable of achieving near 
infrared (NIR) imaging and adenosine-5’- 
triphosphate (ATP)-responsive anticancer drug 
release (Figure 1). ATP, as the essential biogenic 
biomolecule for cellular energy metabolism and 
signaling[38-41], is recently attracting considerable 
interest as an effective stimulus due to the distinct 
difference in the ATP levels between extracellular and 
intracellular milieu.[42-45] This doxorubicin (DOX) 
encapsulated nanocarrier (designated DOX/PFFP 
NP) comprises of ATP-responsive and NIR-emissive 
FPBA- and PEG-grafted conjugated polymer 
(designated PFFP) (Figure 1). The NIR fluorescent 
core of the NP is hydrophobic conjugated polymer, 
which contains dithiophene-thienopyrazine[46] 
moiety as an NIR imaging agent. The 
3-fluoro-4-carboxyphenylboronic acid (FPBA) tags on 
the nanocarrier surface are designed as binding sites 
to ATP through a specific recognition[47, 48]. At the 
intracellular ATP concentration, the FPBA groups 
interact with ATP to yield water-soluble conjugated 
polyelectrolytes[49], which promotes the disassembly 
of the drug nanocarrier. 
After intravenous (i.v.) injection, DOX/PFFP 
NPs preferentially accumulate at the tumor sites by 
the enhanced permeability and retention (EPR) 
effect[1], and the binding affinity toward the 
overexpressed glycans or sialic acids on the surface of 
cancer cells[50-53], followed by cellular 
internalization through endocytosis (Figure 1C). The 
hydrolysis of borate ester component promotes 
endosomal escape of the NPs, allowing the efficient 
transport of DOX/PFFP into the cytosol. At a 
significantly higher ATP level in the cytosol compared 
with that in the extracellular fluid[42, 45], DOX/PFFP 
NPs dissociate with the subsequent release of the 
cargo. The released DOX could accumulate into the 
nuclei to induce DNA damage-mediated cytotoxicity 
and apoptosis[54].  
 
 
Figure 1. Schematic representation of the ATP-triggered DOX release system. (A) Chemical structure of the conjugated polymer (PFFP) described in the text. (B) The main 
components of DOX/PFFP nanoparticles (NPs): near-infrared (NIR) fluorescent core and flexible hydrophilic PEG chains as shell by self-assembly of amphiphilic conjugated 
polymer (PFFP), and the 3-fluoro-4-carboxyphenylboronic acid (FPBA) tags on the surface designed as binding sites for ATP. (C) ATP-responsive delivery of DOX by DOX/PFFP 
NPs to nuclei for the targeted cancer therapy. 
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Methods 
Materials 
All chemicals were purchased from 
Sigma-Aldrich unless otherwise specified and were 
used as received. Monomer 2 and 3 were purchased 
from Beijing Allmers Chemical S&T Co., Ltd. (Beijing, 
China). 
Synthesis of CP-NH2 
The synthesis route to the conjugated polymers 
containing amine groups (CP-NH2) was shown in 
Figure S1. Briefly, 2,7-dibromo-9,9-bis(3- 
aminopropyl) fluorene (1) was prepared according to 
the reported reference [55]. Monomer 1 (0.22 g, 0.5 
mmol), monomer 2 (0.62 g, 1 mmol), monomer 3 (0.24 
g, 0.5 mmol), and Pd(PPh3)4 (50 mg) were dissolved in 
a degassed mixture of toluene (25 mL) and K2CO3 
aqueous solution (2 mol/L, 12.5 mL). The mixture was 
stirred at 85-90 °C for 2 days under an argon 
atmosphere. After cooling to room temperature, the 
mixture was extracted with chloroform, washed with 
brine and distilled water, and then precipitated from 
acetone to afford a brown solid with 57% yield. 1H 
NMR (300 MHz, CDCl3, δ): 7.36-7.78 (m, Ar-H), 2.75 
(s, pyrazine-CH3), 1.90-2.20 (m, Fluorene-CH2, 
N-CH2), 0.72-0.90 (m, -CH2CH2CH3). 13C NMR (75 
MHz, CDCl3, δ): 152.12, 149.38, 143.39, 141.05, 139.91, 
137.72, 133.9, 130.5, 129.70, 128.74, 127.63, 123.78, 
120.57, 53.14, 50.19, 48.55, 46.31, 37.10, 32.17, 30.06, 
29.43, 27.33, 26.42, 23.22, 19.44, 15.72. The molecular 
weight of CP-NH2 was determined by GPC 
(calibrated by polystyrene standard). The 
weight-average molecular weight was 11 000 g/mol, 
and the polydispersity was 1.2. MS (MALDI-TOF, 
m/z): 12995 (Figure S2). 
Synthesis of PFFP and PFP 
CP-NH2 was allowed to react with 
3-fluoro-4-carboxyphenylboronic acid and 
methoxypoly(ethylene glycol) succinimidyl ester 
(PEG-SC), coupling their carboxyl groups with the 
amino groups of the conjugated polymer to yield 
conjugated polymer-g-FPBA/PEG (PFFP) (Figure S1). 
Briefly, CP-NH2 (0.12 mmol) and 
4-dimethylaminopyridie (DMAP) (0.04 mmol) were 
added in anhydrous DMSO (25 mL) solution 
containing FPBA (0.15 mmol) and N, 
N’-dicyclohexylcarbodiimide (DCC) (0.15 mmol) in 
an ice bath with argon. The mixture was firstly stirred 
for 1 h at 0 °C, and further 24 h at room temperature. 
Then, PEG-SC (0.09 mmol) was added and further 
stirred at room temperature for 3 days. After being 
placed in a fridge, 1,3-dicyclohexylurea (DCU) was 
filtered off, and the filtrate was further dialyzed 
against distilled water using a dialyser with a cutoff 
molecular weight of 8000-10 000 g/mol for 2 days. 
The resulting aqueous solution was then freeze-dried 
and the product was vacuum-dried overnight to yield 
PFFP. 1H NMR (300 MHz, CDCl3, δ): 7.42-8.00 (m, 
Ar-H), 6.83 (s, -NH-CO), 3.56-3.64 (m, 
CH3-O-CH2-CH2-O-), 2.75 (s, pyrazine-CH3), 2.0-2.20 
(m, Fluorene-CH2, N-CH2), 0.74-0.88 (m, 
-CH2CH2CH3). 13C NMR (75 MHz, CDCl3, δ): 161.55, 
157.64, 152.25, 146.88, 141.39, 139.54, 138.25, 136.26, 
132.38, 130.22, 129.11, 128.96, 127.84, 125.79, 123.50, 
113.8, 66.63, 65.87, 55.06, 53.28, 46.95, 45.76, 36.13, 
31.52, 30.44, 29.43, 28.20, 25.89, 23.08, 19.93, 14.28. 11B 
NMR (160.4 MHz, DMSO-d6, δ): 26.9. In addition, 
conjugated polymer-g-PEG (PFP) (without FPBA) was 
prepared by the same methods. 
Preparation and characterization of 
DOX-loaded nanoparticles DOX/PFFP NPs 
DOX/PFFP nanoparticles were prepared by a 
solvent-exchange method[56]. Briefly, PFFP (1.5 mg) 
was dissolved in THF (2 mL) and stirred for 3 h at 
room temperature for further use. A mixture solution 
of dimethyl sulfoxide (DMSO) (0.5 mL) and THF (1 
mL) containing triethanolamine-treated doxorubicin 
hydrochloride (4 mg/mL) was stirred for 30 min at 
room temperature for further use. Then 0.1 mL of 
DOX was added into 2 mL of PFFP solution for 
stirring 10 min. 4 mL of deionized water was slowly 
added into the PFFP and DOX solution by syringe 
with stirring (850 rpm) at speed of 2 mL/h. The 
mixture solution was dialyzed against distilled water 
for 24 h, using a membrane with a cutoff molecular 
weight of 8000-10000 g/mol. The resulting 
nanoparticles (DOX/PFFP NPs) were cleaned and 
collected by repeating a procedure of centrifugation at 
10 000 rpm and re-suspension in distilled water three 
times. The product was stored at 4 °C. The loading 
amount of DOX was determined by measuring the 
fluorescence intensity of DOX via microplate reader 
(Infinite M200 PRO, Tecan). DOX/PFFP NPs was 
characterized by the Zetasizer (Nano ZS, Malvern), 
TEM (JEM-2000FX, Hitachi), and SEM (Hitachi s-4800 
high resolution SEM). Ultraviolet-visible (UV-vis) 
absorption spectra were collected on a Mapada Model 
UV-1800 spectrophotometer. Fluorescence spectra 
were measured on Horiba Jobin Yvon Model 
FM-4NIR spectrophotometer. In addition, DOX/PFP 
NPs were prepared by the same methods. 
In vitro ATP-triggered DOX release 
DOX/PFFP NPs (0.6 mL) with 4.8 μg of DOX 
were added into a dialysis tube (3.5K MWCO) 
(Slide-A-Lyzer, Thermo Scientific) embedded into 1 
mL of PBS buffer solution (pH=7.4) containing 
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different concentrations of ATP, and gently shaken at 
37 °C in a shaker (New Brunswick Scientific). At 
predetermined time intervals, the total buffer solution 
was withdrawn, followed by replacing with 1mL of 
fresh buffer solution with the same ATP 
concentration. The fluorescence intensity of DOX 
released was measured at 595 nm with an excitation 
wavelength of 480 nm by a microplate reader (Infinite 
M200 PRO, Tecan). 
Cell culture 
HepG2 cells were obtained from Tissue Culture 
Facility of UNC Lineberger Comprehensive Cancer 
Center and cultured in Dulbecco's Modified Eagle 
Medium (DMEM) with 10% (v:v) fetal bovine serum 
(FBS), 100 U/mL penicillin, and 100 μg/mL 
streptomycin. 
Intracellular ATP-dependent DOX 
release 
HepG2 cells (1×105 cells per well) were seeded in 
a confocal microscopy dish. After cultured for 24 h, 
the cells were incubated with DOX/PFFP NPs (2 
μg/mL DOX concentration) at 37 °C for 2 h, and then 
washed by PBS twice, following by incubation with 
fresh FBS-free culture medium for additional 0 h or 4 
h. Subsequently, the cells were stained by 
Ly-so-Tracker Green (50 nM) (Life Technologies) at 37 
°C for 30 min and Hoechst 33342 (1 μg/mL) (Life 
Technologies) at 37 °C for 10 min. Finally, the HepG2 
cells were washed by PBS twice and observed via 
confocal laser scanning microscope (LSM710, Zeiss). 
Additionally, low temperature (4 °C) and iodoacetic 
acid (IAA) at 37 °C were used to inhibit ATP 
production in the cells. After incubated with 
DOX/PFFP NPs (2 μg/ml DOX concentration) at 37 
°C for 2 h and then washed by PBS twice, the cells 
were incubated at 4 °C or with IAA (100 mM) at 37 °C 
for additional 4 h. For Hoechst 33342 detection, the 
excitation wavelength was 405 nm, and the emission 
filter was 455±20nm; For LysoTracker Green, DOX, 
PFFP detection, the excitation wavelength was 488 
nm, and the emission filter band was 510±10nm, 
605±20nm, and 710±30nm, respectively. 
Flow cytometry quantification of DOX in 
HepG2 cell nuclei 
HepG2 cells (1×105 cells per well) were seeded in 
six-well plates. After cultured for 48 h, the cells were 
incubated with DOX/PFFP NPs (2 μg/ml DOX 
concentration) at 37 °C for 2 h, and then washed by 
PBS twice, following by incubation with fresh 
FBS-free culture medium at different conditions for 
additional 4 h to ensure the released DOX to migrate 
into the cell nuclei, including normal temperature (37 
°C), low temperature (4 °C), and with IAA (100 mM) 
at 37 °C. Finally, after trypsinization, HepG2 cells 
were suspended at a concentration of 5 ×106 cells/mL 
for 10 min at 4 °C in a 100 mM NaCl solution with 1 
mM EDTA, 1% Triton X-100 and 10 mM Tris buffer 
(pH 7.4). The suspension was then centrifuged (15 
min, 800 g), and the resulting precipitate of cell nuclei 
was separated from the supernatant cell cytosol, 
finally re-suspended in 0.2 mL of 1× PBS. The 
fluorescence intensity of DOX in the cell nuclei was 
measured using flow cytometry (CytoFLEX Flow 
Cytometry, Beckman Coulter Ltd.). In addition, 
untreated group, PFFP NPs, DOX/PFP NPs, and free 
DOX as control were analyzed by the same methods. 
In vitro cytotoxicity[57] 
HepG2 cells (5 × 103 cells/well) were seeded in 
96-well plates. After incubation for 24 h, the cells were 
then treated with different samples at different DOX 
concentrations and further incubated for 24 h at 37 °C, 
including free DOX solution, DOX/PFP NPs, and 
DOX/PFFP NPs. Followed 20 μL of the MTT (5 
mg/mL) was added into the HepG2 cells. After 
incubation for 4 h, the medium was replaced with 
DMSO (150 μL). The absorbance was measured at 
wavelength of 570 nm by the microplate reader 
(Infinite M200 PRO, Tecan). 
Animals and tumor model 
The animals were treated in accordance with the 
Guide for Care and Use of Laboratory Animals, 
approved by the Model Animal Research Center 
(MARC) of Nanjing University. HepG2 tumor model 
was established by subcutaneous injection of HepG2 
cells (1 × 106) into the selected positions of the nude 
mice (6 weeks of age, purchased from MARC of 
Nanjing University). The tumor size was monitored 
by a vernier caliper, and the tumor volume (V) was 
calculated as V=L*W2/2, where L and W were the 
length and width of the tumor, respectively. 
In vivo imaging study 
When the HepG2 tumors reached 200-400 mm3, 
the mice were intravenously injected by DOX/PFFP 
NPs at PFFP dose of 3.6 mg/kg. The real-time NIR 
fluorescence imaging was performed using a 
MaestroTM EX fluorescence imaging system 
(Cambridge Research & Instrumentation, USA) after 
4, 12, and 24 h post-injection. After the 24 h scanning, 
the mice were euthanized. The tumors and major 
organs were harvested, and subjected for ex vivo 
imaging. Region-of-interests were circled around the 
organs, and the fluorescence intensities were analyzed 
by Living Image Software. The excitation wavelength 
is 595 nm, and in vivo fluorescence imaging was 
collected from 680 to 780 nm (with 10 nm step). The 
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autofluorescence of mice was removed by spectral 
unmixing software. Besides, DOX/PFP NPs were 
analyzed by the same methods. 
To evaluate the metabolism process of 
DOX/PFFP NPs in mice by CLSM, the mice were 
intravenously injected by DOX/PFFP NPs at PFFP 
dose of 3.6 mg/kg, and then real-time NIR 
fluorescence imaging was performed within 5 days. 
In vivo antitumor efficacy 
The tumor-bearing mice were weighed and 
randomly divided into different groups when the 
tumor volume reached 50 mm3, and subjected to the 
following treatments: 1. Saline; 2. DOX solution; 3. 
DOX/PFP NPs; 4. DOX/PFFP NPs. The mice were 
intravenously injected with same DOX concentration 
(DOX of 2 mg kg-1) in all DOX formulations every 
other day for 12 days, meanwhile the tumor sizes 
were measured. At day 14, the mice were euthanized, 
and the tumors were collected, weighed, washed with 
saline thrice and fixed in the 10% neutral-buffered 
formalin. For the hematoxylin and eosin (HE) and the 
terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) apoptosis staining, the 
formalin-fixed tumors were prepared by Nanjing 
Drum Tower Hospital, and observed by the 
fluorescence microscope (IX71, Olympus). 
Statistical analysis 
Data are given as Mean ± SD. Statistical 
significance was performed using two-tailed 
Student’s t-test. Statistical significance was set at *P < 
0.05, and extreme significance was set at **P < 0.01. 
Results and Discussion 
Synthesis and characterization of DOX/PFFP 
NPs 
To substantiate our design, we firstly 
synthesized an ATP-responsive and NIR-emissive 
conjugated polymer PFFP (Figure 1A) by alternating 
copolymerization of fluorene- (a high-efficient blue 
emitting unit) and dithiophene-thienopyrazine- (a 
unit to effectively shift emission maximum to NIR 
wavelength[46]) containing monomers via the Suzuki 
cross-coupling reaction. Then the branched chains 
were further modified with FPBA and PEG by 
amidation reactions[55] (Figure S1). The obtained 
PFFP was an amphiphilic polymer, which was 
utilized to encapsulate DOX by self-assembly (Figure 
1B). The fluorescent core of the nanoparticles was 
hydrophobic π-conjugated backbone, and the flexible 
hydrophilic PEG chains were selected due to its 
biocompatibility. The electron withdrawing amide 
carbonyl and fluorine on the FPBA moiety reduce the 
pKa of boronic acid monomer, which allows its 
response to ATP at a physiological pH. At the 
intracellular ATP concentration, the FPBA groups on 
the branched chains were expected to interact with 
ATP, resulting in water-solubility of the conjugated 
polymer, thus promoting disassembly of DOX/PFFP 
NPs. The signal at 26.9 ppm in 11B NMR spectrum of 
PFFP is characteristic of trigonal boronic acid, 
indicated the successful conjugation. The ratio of 
FPBA group and the PEG group was determined as 
2/1 via 1H-NMR.  
The rigid π-conjugated backbone is hydrophobic, 
while the grafted PEG chains easily dissolve in water. 
Thus this amphiphilic copolymer tends to form robust 
and spherical nanoparticles (NPs) in the aqueous 
solution. The NPs in aqueous suspension shown an 
average hydrodynamic diameter of 116 nm with a 
narrow size distribution measured by dynamic light 
scattering (DLS) (Figure 2A). The morphology of the 
conjugated polymer nanoparticles was observed 
using TEM and SEM (inset of Figure 2A and Figure 
2C). The spherical shape of the nanoparticles was 
clearly distinguished with a diameter of slightly 
smaller than that in aqueous suspension due to the 
collapse of outmost PEG layers during the drying 
process. The DOX loading capacity was measured to 
be 20 % (wt/wt). The UV/Vis absorption spectrum of 
PFFP NPs in aqueous suspension displayed two 
absorption bands at 392 and 583 nm, respectively 
(Figure 2B), which arise from the light absorption by 
the π-electron system of the conjugated backbone. The 
maximum emission wavelength of PFFP was 720 nm, 
indicating that the NPs have NIR emission suitable for 
in vivo imaging, with a Stokes shift of approximately 
140 nm (excited at 480 nm) (Figure 2B and Figure S3). 
In vitro ATP-triggered DOX release from 
DOX/PFFP 
To investigate the ATP-responsive capability, 
PFFP and DOX/PFFP NPs were incubated at 0.4 mM 
and 4 mM ATP concentrations, which represent the 
typical ATP level in the extracellular fluid and 
intracellular cytosol, respectively[42-45]. As shown in 
Figure 2C and Figure S4, a remarkable disassembly of 
the NPs was observed in the presence of 4 mM ATP 
concentration. In contrast, the NPs were nearly intact 
when treated with 0.4 mM ATP. DLS measurement 
also confirmed that the NPs were responsive to the 
high concentrations of ATP (Figure 2D and Figure S4). 
To evaluate their colloidal stability, DOX/PFFP NPs 
were incubated in the DI water, phosphate-buffered 
saline (PBS, pH 7.4), and Dulbecco's Modified Eagle 
Medium (DMEM). The average sizes of the 
nanoparticles had no significant change after 
incubation for 7 days (Figure 2E). Of note, the 
nanoparticles can maintain high stability in the 
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glycemic concentration (5 mM). Moreover, the 
average sizes and morphology of the nanocarriers 
have no significant change after incubation with 1 
mM H2O2 for 24 h at 37 °C (Figure S5). 
The ATP-triggered DOX release behaviors of 
DOX/PFFP NPs were further tested (Figure 2F). In 
the presence of 0.4 mM ATP solution (pH=7.4), only 
5% of DOX was released from DOX/PFFP NPs in the 
first 4 h and about 20% was released within 24 h. In 
the same buffer solution with 4 mM ATP, comparable 
to intracellular ATP levels, the release of DOX was 
dramatically accelerated. About 18% of DOX was 
released from DOX/PFFP NPs in the first 4 h and 
more than 55% was released within 24 h. It is also 
noteworthy that the release of DOX from DOX/PFP 
NPs, where the lack of FPBA groups in PFP led to the 
nanoparticles without ATP sensitivity, is slow even in 
the presence of 4 mM ATP. It indicated that FPBA 
groups were essential for the fast release of the 
intercalated DOX from the nanoparticles in an 
ATP-rich environment. 
 
 
Figure 2. Characterization and in vitro ATP-responsive DOX release from DOX/PFFP. (A) Hydrodynamic size distribution and TEM image (inset) of DOX/PFFP NPs. Scale bar 
is 200 nm. (B) Normalized UV/Vis absorption and emission spectra of PFFP NPs and DOX/PFFP NPs (excitation at 480 nm). (C) SEM images and (D) size distribution of 
DOX/PFFP NPs at different ATP concentration. Scale bars are 200 nm. (E) Average size changes of DOX/PFFP NPs when incubated in DI water, PBS buffer, DMEM, and glucose 
for 7 days. (F) In vitro release of DOX from DOX/PFFP NPs in 0.4 mM, 4 mM ATP, and DOX/PFP NPs (without ATP sensitivity) in 4 mM ATP. Error bars indicate SD (n = 3). 
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Figure 3. Intracellular delivery of (A) DOX/PFFP NPs and (B) DOX/PFP NPs into HepG2 cells at different time observed by CLSM. The endosomes and lysosomes were stained 
by LysoTracker Green, and the nuclei were stained by Hoechst 33342. Merged (DOX/ LysoTracker/ Hoechst). Scale bars are 20 μm. 
 
Intracellular ATP-triggered DOX release from 
DOX/PFFP 
The intracellular delivery of DOX/PFFP NPs 
was explored in the human liver carcinoma (HepG2) 
cells using confocal laser scanning microscopy 
(CLSM). The HepG2 cells were incubated with 
DOX/PFFP NPs for 2 h, and then incubated with 
fresh culture medium for an additional 4 h at 37 °C. 
As shown in Figure 3A, most of the endocytic 
DOX/PFFP NPs were located in the endolysosomes 
judged by the yellow fluorescence during the first 2h 
of the cellular uptake of DOX/PFFP NPs. Notably, as 
evidenced by the magenta fluorescence, a significant 
increase of DOX fluorescence intensity in the nuclei 
was observed after an additional incubation for 4h. 
Moreover, we studied the microscopy images of 
DOX/PFP NPs as control, as shown in Figure 3B. 
Most of the endocytic DOX/PFP NPs were located in 
the endolysosomes, and no significant DOX 
fluorescent signal in the nuclei was observed after an 
additional incubation for 4h. 
To further demonstrate DOX/PFFP 
NPs-mediated intracellular ATP-triggered DOX 
release, HepG2 cells were incubated with DOX/PFFP 
NPs at a low temperature (4 °C) or in the presence of 
iodoacetic acid (IAA)[42, 58], which can inhibit the 
ATP generation. Cell incubation at 4 °C or with IAA at 
37 °C both led to a significant decrease in ATP 
generation within the cells. The cells incubated both at 
4 °C and with IAA at 37 °C showed insignificant DOX 
fluorescence signals in the nuclei (Figure 4A). We also 
tracked the intracellular ATP-triggered hydrolysis of 
PFFP NPs. As shown in Figure S6, PFFP were mainly 
distributed in the cytoplasm, and as contrast, the cells 
incubated both at 4 °C and with IAA at 37 °C showed 
that PFFP was mainly located in the endolysosomes 
indicated by the white fluorescence. In addition, the 
quantitative analysis of the cellular uptake of DOX by 
HepG2 cell nuclei was carried out using the flow 
cytometry. As shown in Figure 4B, more DOX 
molecules were found within DOX/PFFP NPs-treated 
cells incubated at 37 °C. However, at 4 °C and with 
IAA at 37 °C, cellular uptake of DOX was inhibited. 
Of note, for DOX/PFP NPs without ATP sensitivity, 
no remarkable DOX fluorescent signal was observed. 
Collectively, these results substantiate that the DOX 
release from DOX/PFFP NPs is an ATP 
level-dependent process. 
The in vitro cytotoxicity of DOX/PFFP NPs 
against HepG2 cells was evaluated by using 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay[57]. Compared with 
ATP-insensitive DOX/PFP NPs, DOX/PFFP NPs 
exhibited obviously enhanced cytotoxicity towards 
HepG2 cells at whole studied DOX concentrations 
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(Figure 4C). Notably, the cytotoxicity of DOX/PFFP 
NPs increased along with the concentration of DOX 
with a half lethal dose (IC50) of 2.1 μg mL-1 at 
incubation time of 24 h. Moreover, efficient 
intracellular release of DOX from DOX/PFFP NPs 
provided higher cytotoxic activity than that of the 
DOX solution (IC50 = 3.8 μg mL-1), indicating that an 
enhanced potency could be achieved using 
ATP-responsive chemotherapy. 
In vivo NIR imaging and antitumor efficacy of 
DOX/PFFP 
The therapeutic efficacy of DOX/PFFP was 
investigated in the mice bearing human liver 
carcinoma tumors. To explore the in vivo NIR imaging 
capability of PFFP, PFFP and DOX/PFFP NPs were 
administrated intravenously into the HepG2 
tumor-bearing mice via tail vein. As shown in Figure 
S7 and 5A, a strong fluorescence signal of PFFP was 
detected at the tumor site after administration for 4 h. 
As time extended, an enhanced PFFP signal was 
found in the tumor than that in the normal tissues, 
suggesting a notable tumor targeting ability of 
DOX/PFFP NPs (Figure 5A). After 24 h post injection, 
the tumor and normal tissues were harvested for ex 
vivo imaging. The strongest fluorescence signal of 
PFFP was observed in the tumor and liver compared 
with other organs (Figure 5B). The quantitative 
region-of-interest (ROI) analysis (Figure 5C) indicated 
that DOX/PFFP NPs allowed high accumulation of 
the drugs at the tumor site via a combination of 
passive and active targeting effects, since 
phenylboronic acid tags on DOX/PFFP NPs can 
selectively bind to the over-expressed glycans or sialic 
acids on the surface of HepG2 cells[50-53]. 
Additionally, the enhanced accumulation of 
DOX/PFFP NPs at tumor site was further validated as 
compared with DOX/PFP NPs (without 
phenylboronic acid) by ex vivo imaging and ROI 
analysis, and the fluorescence signal at the tumor site 
of DOX/PFFP-treated mice was approximately 2.5- 
times as much as that of DOX/PFP-treated mice 24 h 
after injection (Figure 5D and 5E). 
 
 
Figure 4. Intracellular 
DOX/PFFP NPs-mediated 
ATP-triggered DOX release. 
(A) Intracellular delivery of 
DOX/PFFP NPs in HepG2 cells 
treated with different 
formulations observed by 
CLSM, including at 37 °C, 4 °C, 
and with the ATP inhibitor 
iodoacetic acid (IAA) at 37 °C. 
The endosomes and lysosomes 
were stained by LysoTracker 
Green, and the nuclei were 
stained by Hoechst 33342. 
Merged (DOX/ 
LysoTracker/Hoechst). Scale 
bar is 20 μm. (B) Flow 
cytometry analysis of the DOX 
fluorescence intensity in 
HepG2 cell nuclei. (C) In vitro 
cytotoxicity of HepG2 cells 
incubated for 24 h with free 
DOX, DOX/PFP NPs (without 
ATP sensitivity), and 
DOX/PFFP NPs. Error bars 
indicate SD (n = 3). 
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Figure 5. In vivo NIR imaging of DOX/PFFP NPs. (A) In vivo fluorescence images of the HepG2 tumor-bearing mice at 4, 12, and 24 h after intravenous injection of DOX/PFFP 
NPs. Arrow indicates the sites of tumor. (B) Ex vivo fluorescence images of the tumor and normal organs collected from the mice 24 h after administration. 1: heart, 2: liver, 3: 
spleen, 4: lung, 5: kidney, 6: tumor. (C) The quantitative region-of-interest (ROI) analysis of fluorescent signals of the tumor and normal organs. The relative fluorescence signal 
biodistribution of DOX/PFFP and DOX/PFP NPs in the tumor and liver: (D) Ex vivo fluorescence images of the tumor and liver collected from the mice 24 h after administration. 
(E) The quantitative region-of-interest (ROI) analysis of fluorescent signals of the tumor and liver. Error bars indicate SD (n = 3). 
 
Figure 6. In vivo fluorescence images of the HepG2 tumor-bearing mice in 5 days after intravenous injection of DOX/PFFP NPs. The red ellipse indicates the site of the tumor. 
 
We also evaluated the metabolism process of 
DOX/PFFP NPs administered intravenously by 
monitoring the PFFP fluorescence signals (Figure 6). 
The NPs were accumulated in the tumor site within 1 
day, and reached the maximum around 1-3 days’ 
post-injection, then started to be discharged from the 
tumor at day 4, which suggested that the successive 
administration every other day was able to maintain a 
high drug concentration in the systemic circulation 
within a prolonged period. These results indicate that 
PFFP has potential to be exploited as an efficient 
drug-delivery system for imaging-guided 
therapeutics[59-61]. Moreover, we further studied the 
biodistribution of DOX and PFFP in various organs by 
quantitative analysis. The mice bearing the tumors 
were intravenously treated with DOX/PFFP NPs at a 
DOX-equivalent dose of 2 mg kg-1. After 24 h post 
injection, the tumor and normal tissues were 
harvested, following by tissue homogenization, acidic 
isopropanol extraction, and fluorometric analysis. As 
shown in Figure S8, DOX/PFFP NPs allowed high 
accumulation of the drugs at the tumor site after 24 h 
of intravenous administration. 
Next, to assess the in vivo efficacy of DOX/PFFP 
NPs for antitumor treatment, the HepG2 
tumor-bearing mice were exposed to treatment with 
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different samples, including the saline as a negative 
control, DOX, DOX/PFP NPs and DOX/PFFP NPs. 
The growth of the tumor was significantly inhibited 
after the treatment with different DOX formulations 
(Figure 7A and 7B). DOX/PFFP NPs and DOX/PFP 
NPs showed the remarkably higher inhibition efficacy 
towards tumor growth than free DOX, which could be 
attributed to the EPR effect of the NPs. Of note, 
DOX/PFFP NPs showed the smaller tumor volume 
compared with that of DOX/PFP NPs, which 
indicated that the efficient intracellular delivery and 
ATP-responsive DOX release of DOX/PFFP NPs 
enabled the reinforcement on the anticancer efficacy. 
Meanwhile, the body weight of the mice treated with 
different samples remained stable except free DOX, 
because of the strong side-effect of DOX to the normal 
organs[54] (Figure 7C). We further applied the 
hematoxylin and eosin (HE) and the terminal 
deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) staining assay to evaluate the treatment 
efficacy (Figure 7D). The images of HE-stained tumor 
tissues treated by DOX/PFFP NPs presented 
prominent necrosis of the tumor cells. The images 
obtained from the TUNEL staining showed the 
highest level of cell apoptosis in the tumor tissue of 
the mice receiving DOX/PFFP NPs. Furthermore, no 
obvious pathological abnormalities were observed in 
normal organs (Figure S9). Taken together, these 
results validated that ATP-responsive DOX/PFFP 
NPs efficiently accumulated at the tumor site, and 
thereby achieved optimal therapeutic efficacy in vivo 
through effective intracellular delivery and 
stimuli-triggered drug release. 
Conclusions 
In summary, we have developed an 
ATP-responsive and NIR-imaging drug delivery 
system for imaging-guided chemotherapy. This 
conjugated polymer-based delivery system presents 
both targeting and controlled release behaviors 
associated with the surrounding ATP levels. This 
system provides guideline to design conjugated 
polymer-based theranostic formulation for enhancing 
efficacy of pinpoint cancer therapy. Further 
investigation includes detailed assessment of systemic 
and long-term toxicity as well as the 
bio-environment-associated photoluminescence 
property of the nanocarriers. 
 
 
Figure 7. Antitumor efficacy of DOX/PFFP NPs. (A) Representative images of the HepG2 tumors after treatment with different samples at day 14 (from top to bottom, 1: saline, 
2: DOX, 3: DOX/PFP NPs, 4: DOX/PFFP NPs. (B) The HepG2 tumor growth curves after treatment with different samples. (C) The body weight variation of HepG2 
tumor-bearing mice during treatment. (D) Histological observation of the tumor tissues stained with HE after treatment with different samples, and detection of apoptosis in the 
tumor tissues after treatment with the TUNEL staining assay. Scale bars are 100 μm. Error bars indicate SD (n = 5); *P < 0.05, **P < 0.01.  
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